

## ASX ANNOUNCEMENT

### JOINT VENTURE FORMED WITH RELEAF GROUP – AUSTRALIA'S LEADING NATIONAL MEDICAL CANNABIS CLINICAL FRANCHISE NETWORK

#### HIGHLIGHTS

- Vitura Health and Australian-based Releaf Group have established an unincorporated joint venture, to combine the leading technology and distribution capabilities of Vitura through the CanView platform and the large network of franchise medical cannabis clinical services of Releaf (**Joint Venture**)
- Joint Venture is expected to increase the volume of medicinal cannabis products prescribed and distributed through the CanView platform, and the number of patients and prescribers registered and using the platform's functionality
- A Releaf-branded version of Vitura's leading CanView platform will be developed for use by Releaf's prescribing doctors, dispensaries and patients
- Releaf's doctors will have access to the Releaf-branded CanView platform to prescribe a wide range of products via the CanView platform's e-prescribing functionality
- Releaf's dispensaries will also be able to dispense products through the Releaf-branded CanView platform. Releaf currently operates clinics and dispensaries in four locations, with ten more expected to be opened by the end of calendar 2023
- Releaf patients will benefit from registering on the Releaf-branded CanView platform and having access to the patient app and, in coming months, the patient treatment tracker app
- The Releaf joint venture is further validation of the market leading CanView platform, being the first branded deployment of the platform with the backing of two state-of-the-art distribution centres

16 MAY 2023

**Melbourne, Australia** – Vitura Health Limited (ASX: VIT) (**Vitura and Company**) is pleased to announce the establishment of an unincorporated joint venture with Australian-based Releaf Group Limited (**Releaf**), a medical cannabis company focused on providing both in-person and telehealth consultations to patients Australia-wide, pursuant to an unincorporated joint venture agreement between Vitura, Burleigh Heads Cannabis Pty Ltd (**BHC**), Releaf and Releaf's subsidiary, Releaf Dispensaries Pty Ltd (**Releaf Wholesaler**), (**JV Agreement**).

The Joint Venture is expected to increase the volume of medicinal cannabis products prescribed and distributed through the CanView platform, and the number of patients and prescribers registered and using the platform's functionality.

VITURA HEALTH LIMITED

ASX : VIT

PO Box 6168, South Yarra

Victoria 3141, Australia

VITURA.COM.AU

BHC'S  
CANVIEW

CDA  
CLINICS

CORTEXA

 **cannadoc**



Releaf operates head office-controlled clinic services as well as being head franchisor to dispensaries in four physical locations across the country, including;

- St Kilda, Victoria;
- Noosa Heads, Queensland;
- Caloundra, Queensland; and
- Fortitude Valley, Queensland.

Under the terms of the JV Agreement, Vitura will provide Releaf, including its franchisees, a Releaf-branded version of Vitura's CanView platform for exclusive use by Releaf's prescribing doctors, dispensaries and patients. The CanView platform will provide Releaf with significant benefits, including increases in workflow efficiencies, seamless compliance reporting, and a turnkey operating solution for new franchisees.

The Joint Venture provides Vitura with exposure to Releaf's physical location business model in high foot traffic locations.

The Vitura and Releaf Joint Venture is further validation of the market leading CanView platform, being the first branded deployment of the platform with the backing of two state-of-the-art distribution centres in Melbourne and on the Gold Coast. It demonstrates that the platform can be deployed for revenue generating activities with rapidly growing strategic partners over the long term.

## Products

Releaf currently operates four clinics and has plans to open a further ten franchises in 2023. As part of the Joint Venture, Vitura, via its wholly owned subsidiary BHC, will import and distribute a number of medical cannabis brands, including the iconic North American brand 'Cookies' and launch the new premium brand 'Symphony', which will be prescribed, sold and distributed via the Releaf-branded CanView platform (provided that they meet Australian regulatory compliance standards) (**Releaf Products**).

Neither Vitura nor BHC have any obligation to purchase, import, supply or otherwise deal with Releaf Products unless and until:

- Releaf provides Vitura with written confirmation from the suppliers of Releaf Products confirming that BHC is authorised to purchase and import the Releaf Products into Australia; and
- BHC enters into an agreement for the supply of the Releaf Products with each of the relevant suppliers,

noting that Releaf must do all things necessary to enable BHC to enter into such an agreement on terms satisfactory to Vitura and BHC.

The Releaf Group will also purchase certain medicines and associated goods specified by Vitura from time to time (**Vitura Products**) exclusively from BHC which will also be prescribed, sold and distributed by Releaf via the Releaf-branded CanView platform.



Releaf must (among other things):

- ensure and procure that all prescribers who have a relationship with a Releaf Group entity have access to use and use the CanView platform for all prescribing activities and only prescribe the products available on the Releaf-branded CanView platform (**Products**) in connection with the Releaf Group, subject to compliance with applicable laws that apply to prescribers (e.g., where alternative prescriptions must be prescribed outside the CanView platform); and
- ensure and procure that all dispensers who have a relationship with a Releaf Group entity have access to use and are able to use the CanView platform for all dispensing activities and are able to dispense the Products in connection with the Releaf Group.

### Term of Joint Venture

The Joint Venture commenced on signing of the JV Agreement and will continue until the JV Agreement is terminated (which can be terminated for convenience upon giving 12 months' prior notice or terminated for cause by giving one business days' notice).

In announcing the Joint Venture, Vitura CEO, Rodney Cocks, said:

"We are very pleased to be forming this JV with Gary Mackenzie and the wider Releaf team. Since launching the new prescriber and patient functionality of our platform earlier this year, we are excited to see the CanView platform being favoured as the complete end to end technology solution within our industry. We look forward to working closely with Releaf to build on their leading position in the physical location clinical space providing better service through leveraging the many benefits of the CanView platform."

Gary Mackenzie, CEO of Releaf, said:

"We are thrilled to partner with Vitura as a wholesale partner and to integrate their leading CanView platform into our clinical services and dispensaries. This Joint Venture will enhance our workflow efficiencies, compliance reporting and provide a turnkey solution for new franchisees. We are excited to offer our patients a seamless experience with the Releaf-branded CanView platform and access to a wider range of medical cannabis products, including the iconic North American brand 'Cookies'."

\*\* ENDS \*\*



## About Releaf Group Limited

Releaf Group Limited is Australia's leading cannabis franchise group currently operating in Australia and launching in the UK in 2023. The company has a vertically integrated business model with a number of wholly-owned subsidiaries ranging from clinics and dispensaries, research and development, training and education, cultivation, manufacturing, and import / export.

- First Australian company to launch a medicinal cannabis clinic and dispensary franchise group
- Unique retail pharmacy model with leading industry brands, integrative medical clinics, and cannabis dispensaries
- Largest medicinal cannabis clinic group and cannabis doctor network in Australia with 20,000+ patients consulted across Releaf locations
- Franchise model allows for fast and efficient nationwide scalability with an assured outlet for wholesale distribution
- Unique brand partnership with Cookies Inc. to cultivate, manufacture and distribute Cookies' genetics in Australia, as well as in-store retail positioning in every Releaf dispensary.

See:

[www.releafgrouppltd.com](http://www.releafgrouppltd.com)  
[www.releafclinics.com.au](http://www.releafclinics.com.au)

## About Vitura Health Limited

Vitura Health Limited (formerly Cronos Australia Limited) is listed on the ASX.

- The Company, via its wholly owned subsidiaries, operates the following businesses:
  - Burleigh Heads Cannabis - operates the market leading prescriber, patient, pharmacy and supplier online platform, CanView, which sells and distributes 230+ product SKUs within Australia from over 30 international and domestic medicinal cannabis producers
  - CDA Clinics - undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis
- The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE:MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia
- The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- See:
  - [www.vitura.com.au](http://www.vitura.com.au)
  - [www.canview.com.au](http://www.canview.com.au)
  - [www.burleighheadscannabis.com](http://www.burleighheadscannabis.com)
  - [www.cortexa.com.au](http://www.cortexa.com.au)
  - [www.cdaclinics.com.au](http://www.cdaclinics.com.au)
  - [www.cannadoc.com.au](http://www.cannadoc.com.au)



**Authorised by**

Rodney Cocks, Chief Executive Officer and Executive Director

**Contact**

**Vitura Health Limited**

Rodney Cocks

Chief Executive Officer and Executive Director

1300 799 491

[info@vitura.com.au](mailto:info@vitura.com.au)

**Media enquiries**

Tim Fogarty

The Civic Partnership

+61 400 179 075

[tim.fogarty@civicpartners.com.au](mailto:tim.fogarty@civicpartners.com.au)

**Forward-looking statements**

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.